The PDUFA Negotiations: Modern Myth
This article was originally published in RPM Report
Executive Summary
Negotiation is supposed to be a two way street--one sides gives a bit, and so does the other side. When it comes to FDA/industry "negotiations" over user fees, that isn't the model at all. Let's call it what it is: a tax on industry, with Congress giving FDA what it wants.
You may also be interested in...
Specialty Drug Tier: When Special Means Expensive
Medicare led the way to create a policy that’s just plain mean. Is there any way back?
Pharma's Stake In Essential Health Benefits
The health reform law lists prescription drugs as one of the 10 categories that plans must include as essential benefits. Decisions on which medicines, how many, and, perhaps most importantly, at what cost to the patient are all questions that HHS needs to determine.
What's Next for Broadcast DTC Advertising?
Defending DTC is one thing. But getting defensive about it is a big mistake.